Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma

Abstract

Malignant peripheral nerve sheath tumors (MPNST) are the deadliest cancer that arises in individuals diagnosed with neurofibromatosis and account for nearly 5% of the 15,000 soft tissue sarcomas diagnosed in the United States each year. Comprised of neoplastic Schwann cells, primary risk factors for developing MPNST include existing plexiform neurofibromas (PN), prior radiotherapy treatment, and expansive germline mutations involving the entire NF1 gene and surrounding genes. PN develop in nearly 30-50% of patients with NF1 and most often grow rapidly in the first decade of life. One of the most important aspects of clinical care for NF1 patients is monitoring PN for signs of malignant transformation to MPNST that occurs in 10-15% of patients. We perform aneuploidy analysis on ctDNA from 883 ostensibly healthy individuals and 28 patients with neurofibromas, including 7 patients with benign neurofibroma, 9 patients with PN and 12 patients with MPNST. Overall sensitivity for detecting MPNST using genome wide aneuploidy scoring was 33%, and analysis of sub-chromosomal copy number alterations (CNAs) improved sensitivity to 50% while retaining a high specificity of 97%. In addition, we performed mutation analysis on plasma cfDNA for a subset of patients and identified mutations in NF1, NF2, RB1, TP53BP2, and GOLGA2. Given the high throughput and relatively low sequencing coverage required by our assay, liquid biopsy represents a promising technology to identify incipient MPNST.

Data availability

Code is available at https://zenodo.org/record/3656943#.YaZZCdDMKUk.

Article and author information

Author details

  1. Austin K Mattox

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7567-5542
  2. Christopher Douville

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    Competing interests
    Christopher Douville, is a consultant to Exact Sciences and is compensated with income and equity..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2510-4151
  3. Natalie Silliman

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  4. Janine Ptak

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  5. Lisa Dobbyn

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  6. Joy Schaefer

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  7. Maria Popoli

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  8. Cherie Blair

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  9. Kathy Judge

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  10. Kai Pollard

    Department of Pediatrics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  11. Christine Pratilas

    Department of Pediatrics, Johns Hopkins University, Baltimore, United States
    Competing interests
    Christine Pratilas, is a paid consultant for Roche/ Genentech and Day One Therapeutics; and receives research funding from Kura Oncology and Novartis Institute of Biomedical Research, all for work that is outside the scope of the submitted manuscript..
  12. Jaishri Blakeley

    Department of Pediatrics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  13. Fausto Rodriguez

    Department of Pathology, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  14. Nickolas Papadopoulos

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    Competing interests
    Nickolas Papadopoulos, is a founder of Thrive Earlier Detection, an Exact Sciences Company. Is a consultant to Thrive Earlier Detection. Holds equity in Exact Sciences. Is a founder of and holds equity in Personal Genome Diagnostics. Is a consultant to Personal Genome Diagnostics. Holds equity in and is a consultant to CAGE Pharma. Owns equity in Neophore and is a consultant to Neophore. The companies named above as well as other companies have licensed previously described technologies related to the work described in this paper from Johns Hopkins University. Is an inventor on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. The terms of all of these arrangements are being managed by Johns Hopkins University in accordance with its conflict-of-interest policies..
  15. Allan Belzberg

    Johns Hopkins Medicine, Baltimore`, United States
    For correspondence
    abelzeb1@jhmi.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1158-2117
  16. Chetan Bettegowda

    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University, Baltimore, United States
    For correspondence
    cbetteg1@jhmi.edu
    Competing interests
    Chetan Bettegowda, is a consultant for Depuy-Synthes, Galectin Therapeutics and Bionaut Labs..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9991-7123

Funding

National Institutes of Health (1R21CA208723-01)

  • Chetan Bettegowda

National Institutes of Health (R37 CA230400)

  • Chetan Bettegowda

National Institutes of Health (U01 CA230691)

  • Chetan Bettegowda

DOD (W81XWH-16-0078)

  • Allan Belzberg
  • Chetan Bettegowda

Doris Duke Charitable Foundation (grant 2014107)

  • Chetan Bettegowda

Burroughs Wellcome Fund (Career Award for Medical Scientists)

  • Chetan Bettegowda

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: All individuals participating in the study provided written informed consent after approval by the institutional review board at The Johns Hopkins IRB00075499. The study complied with the Health Insurance Portability and Accountability Act and the Deceleration of Helsinki.

Copyright

© 2022, Mattox et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,056
    views
  • 204
    downloads
  • 13
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Austin K Mattox
  2. Christopher Douville
  3. Natalie Silliman
  4. Janine Ptak
  5. Lisa Dobbyn
  6. Joy Schaefer
  7. Maria Popoli
  8. Cherie Blair
  9. Kathy Judge
  10. Kai Pollard
  11. Christine Pratilas
  12. Jaishri Blakeley
  13. Fausto Rodriguez
  14. Nickolas Papadopoulos
  15. Allan Belzberg
  16. Chetan Bettegowda
(2022)
Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma
eLife 11:e74238.
https://doi.org/10.7554/eLife.74238

Share this article

https://doi.org/10.7554/eLife.74238

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Sofia V Krasik, Ekaterina A Bryushkova ... Ekaterina O Serebrovskaya
    Research Article

    The current understanding of humoral immune response in cancer patients suggests that tumors may be infiltrated with diffuse B cells of extra-tumoral origin or may develop organized lymphoid structures, where somatic hypermutation and antigen-driven selection occur locally. These processes are believed to be significantly influenced by the tumor microenvironment through secretory factors and biased cell-cell interactions. To explore the manifestation of this influence, we used deep unbiased immunoglobulin profiling and systematically characterized the relationships between B cells in circulation, draining lymph nodes (draining LNs), and tumors in 14 patients with three human cancers. We demonstrated that draining LNs are differentially involved in the interaction with the tumor site, and that significant heterogeneity exists even between different parts of a single lymph node (LN). Next, we confirmed and elaborated upon previous observations regarding intratumoral immunoglobulin heterogeneity. We identified B cell receptor (BCR) clonotypes that were expanded in tumors relative to draining LNs and blood and observed that these tumor-expanded clonotypes were less hypermutated than non-expanded (ubiquitous) clonotypes. Furthermore, we observed a shift in the properties of complementarity-determining region 3 of the BCR heavy chain (CDR-H3) towards less mature and less specific BCR repertoire in tumor-infiltrating B-cells compared to circulating B-cells, which may indicate less stringent control for antibody-producing B cell development in tumor microenvironment (TME). In addition, we found repertoire-level evidence that B-cells may be selected according to their CDR-H3 physicochemical properties before they activate somatic hypermutation (SHM). Altogether, our work outlines a broad picture of the differences in the tumor BCR repertoire relative to non-tumor tissues and points to the unexpected features of the SHM process.

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark A LaBarge
    Research Article Updated

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.